February 16,2006
Senator Grassley's Statement for the Record regarding FDA's Approval Process
Please see the following two documents attached as related files:
(1) Grassley Statement from the Feb. 16 Congressional Record
(2) Report of the Committee Staff Review of the FDA’s Approval Process for the Vagus Nerve Stimulation Therapy System for Treatment-Resistant Depression
Next Article Previous Article
Recent News
- CBO Confirms: Biden-Harris Election Year Medicare Cost-Shifting Policy Will Cost Taxpayers Billions in 2025
- Crapo Statement at Hearing on Women's Health
- Crapo: Idahoans Deserve More Affordable, Accessible Health Care, Not Wasteful Taxpayer-Funded Mandates
- Crapo Statement at Hearing on the Inflation Reduction Act’s Health Care Provisions
- Crapo: Congress Must Extend 2017 Tax Law